Schizophrenia and Hospital Admissions for Cardiovascular Events in a Large Population: The APNA Study
- PMID: 35050235
- PMCID: PMC8778060
- DOI: 10.3390/jcdd9010025
Schizophrenia and Hospital Admissions for Cardiovascular Events in a Large Population: The APNA Study
Abstract
(1) Background: Patients with schizophrenia have higher mortality, with cardiovascular diseases being the first cause of mortality. This study aims to estimate the excess risk of hospital admission for cardiovascular events in schizophrenic patients, adjusting for comorbidity and risk factors. (2) Methods: The APNA study is a dynamic prospective cohort of all residents in Navarra, Spain. A total of 505,889 people over 18 years old were followed for five years. The endpoint was hospital admissions for a cardiovascular event. Direct Acyclic Graphs (DAG) and Cox regression were used. (3) Results: Schizophrenic patients had a Hazard Ratio (HR) of 1.414 (95% CI 1.031-1.938) of hospital admission for a cardiovascular event after adjusting for age, sex, hypertension, type 2 diabetes, dyslipidemia, smoking, low income, obesity, antecedents of cardiovascular disease, and smoking. In non-adherent to antipsychotic treatment schizophrenia patients, the HR was 2.232 (95% CI 1.267-3.933). (4) Conclusions: Patients with schizophrenia have a higher risk of hospital admission for cardiovascular events than persons with the same risk factors without schizophrenia. Primary care nursing interventions should monitor these patients and reduce cardiovascular risk factors.
Keywords: cardiovascular; hospital admissions; prospective cohort; schizophrenia.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the study’s design, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
Variability in the Control of Type 2 Diabetes in Primary Care and Its Association with Hospital Admissions for Vascular Events. The APNA Study.J Clin Med. 2021 Dec 14;10(24):5854. doi: 10.3390/jcm10245854. J Clin Med. 2021. PMID: 34945149 Free PMC article.
-
Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population?Clin Exp Hypertens. 2017;39(5):441-447. doi: 10.1080/10641963.2016.1267200. Epub 2017 Jun 7. Clin Exp Hypertens. 2017. PMID: 28590147
-
Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.Eur Arch Psychiatry Clin Neurosci. 2014 Feb;264(1):3-28. doi: 10.1007/s00406-013-0436-x. Epub 2013 Aug 13. Eur Arch Psychiatry Clin Neurosci. 2014. PMID: 23942824
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
[Schizophrenia, diabetes mellitus and antipsychotics].Encephale. 2004 Jul-Aug;30(4):382-91. doi: 10.1016/s0013-7006(04)95452-8. Encephale. 2004. PMID: 15538314 Review. French.
Cited by
-
Evaluation Expression of the Caspase-3 and Caspase-9 Apoptotic Genes in Schizophrenia Patients.Clin Psychopharmacol Neurosci. 2023 Feb 28;21(1):171-178. doi: 10.9758/cpn.2023.21.1.171. Clin Psychopharmacol Neurosci. 2023. PMID: 36700323 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources